UroGen Pharma (URGN) Cash & Equivalents (2016 - 2026)

UroGen Pharma (URGN) has reported Cash & Equivalents for 11 consecutive years, with $110.0 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Equivalents rose 5.7% year-over-year to $110.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $110.0 million (up 5.7% YoY) and the FY2025 annual result came in at $110.7 million, down 35.61% from the prior year.
• Cash & Equivalents retreated to $110.0 million in Q1 2026 per URGN's latest filing, from $110.7 million in the prior quarter.
• Over the last five years, Cash & Equivalents for URGN reached as high as $220.0 million in Q2 2024 and fell as low as $20.1 million in Q2 2023.
• A 5-year average of $97.8 million and a median of $104.0 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 65.33% — and 2024, when it jumped 992.92%.
• Year by year, Cash & Equivalents stood at $55.4 million in 2022, then jumped by 71.46% to $95.0 million in 2023, then jumped by 81.04% to $172.0 million in 2024, then sank by 35.61% to $110.7 million in 2025, then retreated by 0.7% to $110.0 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $110.0 million, $110.7 million, and $90.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.